Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2022-10-31 Purchase |
2022-11-02 4:09 pm |
Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner |
1,500,000 | $2 | $3,000,000 | 6,951,111 (Indirect Direct) |
View |
| 2022-08-23 Sale |
2022-08-24 4:47 pm |
Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer |
3,325 | $3.47 | $11,538 | 266,121 (Direct) |
View |
| 2022-08-18 Sale |
2022-08-22 8:05 pm |
Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer |
28,675 | $3.6966 | $105,999 | 269,446 (Direct) |
View |
| 2022-07-05 Sale |
2022-07-07 4:30 pm |
Taysha Gene Therapies Inc. | TSHA | PRASAD SUYASH CMO and Head of R&D |
12,861 | $3.705 | $47,650 | 530,589 (Direct) |
View |
| 2022-06-29 Sale |
2022-07-01 6:55 pm |
Taysha Gene Therapies Inc. | TSHA | PRASAD SUYASH CMO and Head of R&D |
50,139 | $3.6515 | $183,081 | 543,450 (Direct) |
View |
| 2022-02-02 Purchase |
2022-02-04 08:28 am |
Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner |
201,602 | $7.7966 | $1,571,810 | 5,429,111 (Indirect Direct) |
View |
| 2022-02-02 Purchase |
2022-02-03 09:21 am |
Taysha Gene Therapies Inc. | TSHA | Nagendran Sukumar Director |
10,000 | $8.01 | $80,100 | 29,226 (Direct) |
View |
| 2022-02-02 Purchase |
2022-02-03 07:04 am |
Taysha Gene Therapies Inc. | TSHA | Donenberg Phillip B. Director |
3,000 | $7.78 | $23,340 | 3,000 (Direct) |
View |
| 2021-11-23 Purchase |
2021-12-08 4:05 pm |
Taysha Gene Therapies Inc. | TSHA | Session R.A. II President and CEO 10% Owner |
42,518 | $12.44 | $529,102 | 9,473,100 (Indirect Direct) |
View |
| 2021-11-24 Purchase |
2021-11-29 5:01 pm |
Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner |
2,202 | $13.19 | $29,044 | 5,249,509 (Indirect Direct) |
View |
| 2021-11-23 Purchase |
2021-11-24 07:58 am |
Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner |
20,000 | $12.54 | $250,800 | 5,247,307 (Indirect Direct) |
View |
| 2021-08-18 Sale |
2021-08-20 5:52 pm |
Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer |
33,000 | $16.88 | $557,023 | 298,121 (Direct) |
View |
| 2021-06-29 Sale |
2021-07-01 6:32 pm |
Taysha Gene Therapies Inc. | TSHA | PRASAD SUYASH CMO and Head of R&D |
79,000 | $22.63 | $1,787,936 | 593,589 (Direct) |
View |
| 2021-05-20 Purchase |
2021-05-24 08:39 am |
Taysha Gene Therapies Inc. | TSHA | Nolan Sean P. Director |
1,170 | $22.35 | $26,150 | 1,092,271 (Indirect Direct) |
View |
| 2021-05-14 Purchase |
2021-05-17 07:48 am |
Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner |
12,000 | $20.98 | $251,760 | 5,227,307 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
Ownership |
2022-10-31 4:05 pm |
N/A N/A |
Taysha Gene Therapies Inc. | TSHA | Audentes Therapeutics Inc. Astellas Pharma Inc. 10% Owner |
0 | $0 | 7,266,342 (Direct) |
View |
| 2022-06-17 Option Award |
2022-06-22 4:41 pm |
N/A 2032-06-17 |
Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director |
15,500 | $0 | 15,500 (Direct) |
View |
| 2022-06-17 Option Award |
2022-06-22 4:40 pm |
N/A 2032-06-17 |
Taysha Gene Therapies Inc. | TSHA | Donenberg Phillip B. Director |
15,500 | $0 | 15,500 (Direct) |
View |
| 2022-06-17 Option Award |
2022-06-22 4:39 pm |
N/A 2032-06-17 |
Taysha Gene Therapies Inc. | TSHA | Nagendran Sukumar Director |
15,500 | $0 | 15,500 (Direct) |
View |
| 2022-06-17 Option Award |
2022-06-22 4:38 pm |
N/A 2032-06-17 |
Taysha Gene Therapies Inc. | TSHA | Nolan Sean P. Director |
15,500 | $0 | 15,500 (Direct) |
View |
| 2022-06-17 Option Award |
2022-06-22 4:37 pm |
N/A 2032-06-17 |
Taysha Gene Therapies Inc. | TSHA | Reape Kathleen Director |
15,500 | $0 | 15,500 (Direct) |
View |
| 2022-06-17 Option Award |
2022-06-22 4:36 pm |
N/A 2032-06-17 |
Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner |
15,500 | $0 | 15,500 (Direct) |
View |
| 2022-04-06 Option Award |
2022-04-08 4:27 pm |
N/A 2032-04-06 |
Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer |
40,000 | $0 | 40,000 (Direct) |
View |
| 2022-04-06 Option Award |
2022-04-08 4:26 pm |
N/A 2032-04-06 |
Taysha Gene Therapies Inc. | TSHA | PRASAD SUYASH CMO and Head of R&D |
40,325 | $0 | 40,325 (Direct) |
View |
| 2022-02-23 Option Award |
2022-02-25 4:20 pm |
N/A 2032-02-23 |
Taysha Gene Therapies Inc. | TSHA | PRASAD SUYASH CMO and Head of R&D |
80,650 | $0 | 80,650 (Direct) |
View |
| 2022-02-23 Option Award |
2022-02-25 4:18 pm |
N/A 2032-02-23 |
Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer |
80,000 | $0 | 80,000 (Direct) |
View |
| 2022-02-23 Option Award |
2022-02-25 4:17 pm |
N/A 2032-02-23 |
Taysha Gene Therapies Inc. | TSHA | Session R.A. II President and CEO 10% Owner |
217,850 | $0 | 217,850 (Direct) |
View |
| 2021-06-17 Option Award |
2021-06-21 5:05 pm |
N/A 2031-06-17 |
Taysha Gene Therapies Inc. | TSHA | Donenberg Phillip B. Director |
15,500 | $0 | 15,500 (Direct) |
View |
| 2021-06-17 Option Award |
2021-06-21 5:04 pm |
N/A 2031-06-17 |
Taysha Gene Therapies Inc. | TSHA | Nagendran Sukumar Director |
15,500 | $0 | 15,500 (Direct) |
View |
| 2021-06-17 Option Award |
2021-06-21 5:02 pm |
N/A 2031-06-17 |
Taysha Gene Therapies Inc. | TSHA | Nolan Sean P. Director |
15,500 | $0 | 15,500 (Direct) |
View |
| 2021-06-17 Option Award |
2021-06-21 5:01 pm |
N/A 2031-06-17 |
Taysha Gene Therapies Inc. | TSHA | Reape Kathleen Director |
15,500 | $0 | 15,500 (Direct) |
View |
| 2021-06-17 Option Award |
2021-06-21 5:01 pm |
N/A 2031-06-17 |
Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director |
15,500 | $0 | 15,500 (Direct) |
View |
| 2021-06-17 Option Award |
2021-06-21 4:59 pm |
N/A 2031-06-17 |
Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner |
15,500 | $0 | 15,500 (Direct) |
View |
| 2020-12-31 Ownership |
2021-02-16 5:45 pm |
N/A N/A |
Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner |
80,000 | $0 | 5,215,307 (Indirect) |
View |
Ownership |
2021-02-16 5:45 pm |
N/A N/A |
Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner |
0 | $0 | 5,215,307 (Indirect) |
View |
| 2021-01-19 Option Award |
2021-01-20 8:22 pm |
N/A 2031-01-19 |
Taysha Gene Therapies Inc. | TSHA | Session R.A. II President and CEO 10% Owner |
199,700 | $0 | 199,700 (Direct) |
View |
| 2021-01-19 Option Award |
2021-01-20 8:21 pm |
N/A 2031-01-19 |
Taysha Gene Therapies Inc. | TSHA | PRASAD SUYASH CMO and Head of R&D |
80,000 | $0 | 80,000 (Direct) |
View |
| 2021-01-19 Option Award |
2021-01-20 8:20 pm |
N/A 2031-01-19 |
Taysha Gene Therapies Inc. | TSHA | Alam Kamran Chief Financial Officer |
70,000 | $0 | 70,000 (Direct) |
View |
| 2020-11-23 Option Award |
2020-11-24 4:42 pm |
N/A 2030-11-23 |
Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director |
31,000 | $0 | 31,000 (Direct) |
View |
| 2020-11-23 Option Award |
2020-11-24 4:41 pm |
N/A 2030-11-23 |
Taysha Gene Therapies Inc. | TSHA | Reape Kathleen Director |
31,000 | $0 | 31,000 (Direct) |
View |